Allscripts-Misys Healthcare Solutionsspent most of 2009 on Cramer’s buy list. If health-care reform was in part about improving efficiencies, he said, then Allscripts and its electronic medical records would help to lead the way. Well, the call paid off, with MDRX returning 136% to shareholders who bought in on his Jan. 22 recommendation.
But after a run like that, profits must be taken. And recent developments in the Senate, namely that Democrats got the votes needed for a complete overhaul of health care, require that Cramer give the stock another look. Then there’s the fact that, despite delivering a better-than-expected quarter on Monday, MDRX still slipped 4.1%. Could the run be over?
That’s the question Cramer put to Allscripts CEO Glen Tullman on Mad Money. Watch the video for the full interview. Call Cramer: 1-800-743-CNBC Questions for Cramerfirstname.lastname@example.org Questions, comments, suggestions for the Mad Money email@example.com
Call Cramer: 1-800-743-CNBC
Questions for Cramerfirstname.lastname@example.org
Questions, comments, suggestions for the Mad Money email@example.com